Fadi S. Farhat

Sidon, JA, LB 
Sidon, JA, LB 

Overview

Fadi Farhat practices practicing medicine in Sidon, Lebanon.

His clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Epithelioid Sarcoma, Lung Adenocarcinoma, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Sidon, JA, Lebanon
Other Locations
Beirut, BA, Lebanon
Mount Lebanon Hospital University Medical Center, Beirut, Hazmiyeh, JL, Lebanon
Hotel Dieu, BA, Lebanon
Lebanon

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

74 Total Publications

Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon.
Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon.
Journal: JCO global oncology
Published: July 22, 2026

Frequently Asked Questions about Fadi S. Farhat

Is Fadi S. Farhat a top-rated expert for PIK3CA-Related Overgrowth Spectrum?

MediFind is an objective health platform that identifies experts based on real-world data. Fadi S. Farhat is classified as an Experienced expert for PIK3CA-Related Overgrowth Spectrum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Fadi S. Farhat participate in research or clinical trials?

Yes. Fadi S. Farhat has published 74 articles and abstracts on conditions like PIK3CA-Related Overgrowth Spectrum. You can view a list of Fadi S. Farhat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Farhat's expertise for a condition
ConditionClose
        View All 25 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile